Which drugs does patent 6,294,540 protect, and when does it expire?
Patent 6,294,540 protects ZIAGEN, EPZICOM, TRIUMEQ, and TRIZIVIR, and is included in five NDAs. There have been zero Paragraph IV challenges on Triumeq, Ziagen, Trizivir, and .
Protection for ZIAGEN has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has eighty-nine patent family members in forty-eight countries.